Maddi Hebebrand, MC, Associate Editor

Antonio Torrelo, MD, emphasizes that genetic testing enhances—but never replaces—clinical judgment in pediatric dermatology.

Doris Day, MD, reframes anti-aging: support fibroblasts, longevity pathways, lifestyle and smart fillers for healthier skin quality.

At SBS 2026, Karan Lal, MD, and Mohammad Goldust, MD, reveal how social media and AI reshape dermatology trust and care.

David Cotter, MD, PhD, underscored the importance of incorporating quality-of-life and mental health measures into psoriasis clinical trials.

Catch up on coverage from the first day of South Beach Symposium 2026.

At MOPD 2026, Nanette Silverberg, MD, and Lisa Swanson, MD, unpack teen AD, fragrance allergy, and social media skin care hype harming barriers.

At MOPD 2026, Kristina Derrick, MD, ScM, links teen acne to hormones and metabolism, highlighting PCOS clues and antiandrogen therapies.

Michael Gold, MD, shares insights on safer device use, peptides, GLP-1s, acne, hair therapies, and more.

MOPD 2026 brings together leading experts to review recent therapeutic advances and practical management strategies in pediatric dermatology.

As SBS kicks off in South Beach Miami, scroll through faces familiar to Dermatology Times presenting at the symposium.

Clinicians assess chronic urticaria prevalence and impact, revealing gaps in understanding and treatment that affect patient care and outcomes.

Explore innovative treatments for skin conditions, including lebrikizumab for pemphigus and low-level laser therapy for hair loss.

James Del Rosso, DO, discusses diagnosis and treatment of mastocytosis and inflammatory conditions.

AbbVie seeks FDA and EMA approval for upadacitinib, a potential breakthrough systemic treatment for non-segmental vitiligo in adults and adolescents.

The new hub for dermatology NPs and PAs offers education, community, and resources to enhance patient care and professional growth.

Fractional CO₂ laser treatment effectively reduces acne scars in Middle Eastern patients, balancing safety and efficacy for darker skin types.

Explore the long-term efficacy of biologics for HS, highlighting bimekizumab's superior outcomes in managing this chronic condition.

Arcutis reveals promising phase 2 results for roflumilast cream in infants with AD, highlighting safety and potential efficacy.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Kyowa Kirin takes full control of rocatinlimab, aiming to address unmet needs in atopic dermatitis while ensuring continuity in clinical trials.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

A phase 2 trial reveals soficitinib's potential to significantly improve symptoms and quality of life in patients with moderate to severe AD.

Dermatology Times is recapping our exclusive expert interviews from the month of January.

Explore the nuanced experiences of drainage in hidradenitis suppurativa (HS), revealing its profound physical and psychological impacts on patients' lives.

James Del Rosso, DO, discusses innovative therapies for chronic hand eczema (CHE), chronic spontaneous urticaria (CSU), and vitiligo.

Explore the nuances of off-label dermatology therapies, emphasizing evidence-based practices, patient communication, and ethical considerations for optimal care.

Ritlecitinib shows promising facial repigmentation in vitiligo patients, with consistent efficacy across diverse demographics in a phase 2b study.

Litifilimab shows significant efficacy in improving skin outcomes for CLE, as demonstrated in the phase 2 LILAC study.

Aclaris Therapeutics' ATI-2138 shows promising rapid hair regrowth in severe alopecia areata models, highlighting its potential as a novel treatment option.